Oscar Health Raises Full-Year Outlook on Strong Q3

What happened

Oscar Health reported Q3 2026 results and raised its full-year 2026 guidance, signaling better-than-expected performance. The company had previously guided for full-year MLR of 82.4%–83.4% and operating income of $250M–$450M, but the raised outlook suggests those targets may be exceeded. The improvement likely reflects lower medical costs, better risk adjustment outcomes, or stronger membership retention, but specifics are not yet disclosed. This is significant because the prior thesis was cautious due to a rising net risk-adjustment payable and the expectation of MLR normalization. The raised guidance reduces the probability of the bear case, but we still need to confirm that the improvement is sustainable and not driven by one-time items.

Implication

Investors should focus on whether the raised outlook is driven by lower medical costs or better risk adjustment performance. If risk adjustment payable stabilized or declined, that would address the primary bear concern. However, if the improvement is due to one-time items like favorable reserve development, the stock may still be vulnerable to future normalization. The company's liquidity remains strong, providing a buffer, but the equity valuation still depends on sustained profitability. Until the Q3 10-Q reveals the underlying drivers, maintain a cautious stance consistent with the previous 'Potential Sell' rating.

Thesis delta

The thesis shifts slightly less bearish as the company raises full-year guidance, indicating that worst-case scenarios may not be materializing. However, the core concern about risk adjustment transfers and MLR normalization has not been conclusively resolved. The positive news suggests that the company is on track to meet or exceed prior operating income targets, but the structural vulnerability to risk adjustment remains until proven otherwise.